Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Epidemiologic and genomewide association studies have linked loss-of-function variants in ANGPTL3, encoding angiopoietin-like 3, with low levels of plasma lipoproteins. METHODS: We evaluated antisense oligonucleotides (ASOs) targeting Angptl3 messenger RNA (mRNA) for effects on plasma lipid levels, triglyceride clearance, liver triglyceride content, insulin sensitivity, and atherosclerosis in mice. Subsequently, 44 human participants (with triglyceride levels of either 90 to 150 mg per deciliter [1.0 to 1.7 mmol per liter] or >150 mg per deciliter, depending on the dose group) were randomly assigned to receive subcutaneous injections of placebo or an antisense oligonucleotide targeting ANGPTL3 mRNA in a single dose (20, 40, or 80 mg) or multiple doses (10, 20, 40, or 60 mg per week for 6 weeks). The main end points were safety, side-effect profile, pharmacokinetic and pharmacodynamic measures, and changes in levels of lipids and lipoproteins. RESULTS: The treated mice had dose-dependent reductions in levels of hepatic Angptl3 mRNA, Angptl3 protein, triglycerides, and low-density lipoprotein (LDL) cholesterol, as well as reductions in liver triglyceride content and atherosclerosis progression and increases in insulin sensitivity. After 6 weeks of treatment, persons in the multiple-dose groups had reductions in levels of ANGPTL3 protein (reductions of 46.6 to 84.5% from baseline, P<0.01 for all doses vs. placebo) and in levels of triglycerides (reductions of 33.2 to 63.1%), LDL cholesterol (1.3 to 32.9%), very-low-density lipoprotein cholesterol (27.9 to 60.0%), non-high-density lipoprotein cholesterol (10.0 to 36.6%), apolipoprotein B (3.4 to 25.7%), and apolipoprotein C-III (18.9 to 58.8%). Three participants who received the antisense oligonucleotide and three who received placebo reported dizziness or headache. There were no serious adverse events. CONCLUSIONS: Oligonucleotides targeting mouse Angptl3 retarded the progression of atherosclerosis and reduced levels of atherogenic lipoproteins in mice. Use of the same strategy to target human ANGPTL3 reduced levels of atherogenic lipoproteins in humans. (Funded by Ionis Pharmaceuticals; ClinicalTrials.gov number, NCT02709850 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, the LDL-C lowering effects of ANGPTL3 inhibition with either monoclonal antibodies or antisense oligonucleotides seems to be LDL receptor (LDLR) independent since marked LDL-C lowering is observed in both Ldlr knock-out (KO) mice6,8 and patients with homozygous familial hypercholesterolemia (hoFH).9”
In the citing paper
“Interestingly, the LDL-C lowering effects of ANGPTL3 inhibition with either monoclonal antibodies or antisense oligonucleotides seems to be LDL receptor (LDLR) independent since marked LDL-C lowering is observed in both Ldlr knock-out (KO) mice6,8 and patients with homozygous familial hypercholesterolemia (hoFH).9”
In the citing paper
“A decrease in VLDL-TG secretion, but not in VLDL apoB secretion or VLDL clearance, was observed in mouse models treated with a monoclonal antibody6 or antisense oligonucleotides8 against ANGPTL3.”
In the citing paper
“In initial studies, treatment with Vupanorsen was associated with a 33%–63% decrease in triglycerides as well as reductions in Apo-C III, remnant and total cholesterol, HDL-C, and LDL-C (169).”
From Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8 (2021) · cites this paper as [169]
In the citing paper
“In a dose-finding study in HTG patients, IONIS-ANGPTL3-LRx reduced TG and LDL-C by up to 63.1% and 32.9%, respectively.82”
From Clinical review on triglycerides (2020) · cites this paper as [82]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Exome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002926 · Cited by 754
Viney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31009-1 · Cited by 754
Self-citationAntisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Self-citationInactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
Dewey, F. E., Gusarova, V., O’Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C. V., Habegger, L., Buckler, D., Lai, K.-M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510926 · Cited by 497
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease
Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507652 · Cited by 493
Targeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491
Self-citationWallace, C., Newhouse, S. J., Braund, P., Zhang, F., Tobin, M., Falchi, M., Ahmadi, K., Dobson, R. J., Marçano, A. C. B., Hajat, C., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2007.11.001 · Cited by 439
Research works printed but not linked: 1
- Romeo S, 2009, J Clin Invest, 119, 70
Cited by
Items 301–400 of 575
Development of New Genome Editing Tools for the Treatment of Hyperlipidemia
Preta, G. (2023) · Cells · doi:10.3390/cells12202466 · Cited by 19
Chan, D. C., & Watts, G. F. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01254-y · Cited by 23
Ruhanen, H., Haridas, P. A. N., Jauhiainen, M., & Olkkonen, V. M. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158791 · Cited by 19
Jia, X., Liu, J., Mehta, A., Ballantyne, C. M., & Virani, S. S. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07082-x · Cited by 19
Triglyceride-Rich Lipoproteins
Kockx, M., & Kritharides, L. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.008 · Cited by 22
Transcriptomic Therapy for Dyslipidemias Utilizing Nucleic Acids Targeted at ANGPTL3
Watts, G. F., Raal, F. J., & Chan, D. C. (2021) · Future Cardiology · doi:10.2217/fca-2021-0096 · Cited by 18
A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?
Ward, N. C., Chan, D. C., & Watts, G. F. (2022) · BioDrugs · doi:10.1007/s40259-022-00520-2 · Cited by 20
Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention
Quispe, R., Sweeney, T. E., Varma, B., Agarwala, A., & Michos, E. D. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01052-4 · Cited by 18
Patel, A. P., & Natarajan, P. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz032 · Cited by 20
Hussain, A., & Ballantyne, C. M. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-100119-013612 · Cited by 22
Liu, Y., Wang, H. H., Yu, M., Cai, L., Zhao, Y., Cheng, Y., Deng, Y., Zhao, Y., Lu, H., Wu, X., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.074737 · Cited by 21
Doi, T., Nordestgaard, B. G., & Langsted, A. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000799 · Cited by 18
Angiopoietin-like 3 inhibition and the liver: less is more?
Oostveen, R. F., Hovingh, G. K., & Stroes, E. S. G. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000898 · Cited by 18
Modder, M., Panhuis, W. I. H., Li, M., Afkir, S., Dorn, A. L., Pronk, A. C. M., Streefland, T. C. M., Lalai, R. A., Pierrou, S. E., Nilsson, S. K., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae195 · Cited by 20
Inferring Half-Lives at the Effect Site of Oligonucleotide Drugs
Jansson‐Löfmark, R., & Gennemark, P. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0739 · Cited by 17
Rajan, S., de Guzman, H. C., Palaia, T. A., Goldberg, I. J., & Hussain, M. M. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100115 · Cited by 19
Management of dyslipidemia in coronary artery disease: the present and the future
Dimitriadis, K. S., Theofilis, P., Iliakis, P., Pyrpyris, N., Dri, E., Sakalidis, A., Σουλαϊδόπουλος, Σ., Tsioufis, P., Fragkoulis, C., Chrysohoou, C. A., et al. (2024) · Coronary Artery Disease · doi:10.1097/mca.0000000000001375 · Cited by 23
Cicero, A. F. G., Bove, M., & Borghi, C. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1416094 · Cited by 18
Shetty, S. K., Walzem, R. L., & Davies, B. S. J. (2020) · Journal of Lipid Research · doi:10.1194/jlr.d119000388 · Cited by 21
LDL-Cholesterol-Lowering Therapy
Pirillo, A., Norata, G. D., & Catapano, A. L. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_361 · Cited by 18
Cognition, Statins, and Cholesterol in Elderly Ischemic Stroke Patients: A Neurologist’s Perspective
Jurcău, A., & Simion, A. (2021) · Medicina · doi:10.3390/medicina57060616 · Cited by 17
Ruhanen, H., Haridas, P. A. N., Minicocci, I., Taskinen, J., Palmas, F., Costanzo, A. D., D’Erasmo, L., Metso, J., Partanen, J., Dalli, J., et al. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158679 · Cited by 18
Reeskamp, L. F., Tromp, T. R., Huijgen, R., Stroes, E. S. G., Hovingh, G. K., & Grefhorst, A. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.11.013 · Cited by 21
Pharmacokinetics of current and emerging treatments for hypercholesterolemia
Tomlinson, B., Chan, P., Zhang, Y., Liu, Z., & Lam, C. W. K. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1749261 · Cited by 17
Huang, K., Yin, S., Xiao, Y., Wang, J., Cui, J., Wang, J., & Bai, Y. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02046-8 · Cited by 18
Shaik, A., & Rosenson, R. S. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07168-0 · Cited by 16
Targeting angiopoietin‐like 3 in atherosclerosis: From bench to bedside
Ling, P., Zheng, X., Luo, S., Ge, J., Xu, S., & Weng, J. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14450 · Cited by 16
Evinacumab for treatment of familial hypercholesterolemia
Warden, B. A., & Duell, P. B. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.1955349 · Cited by 16
Vahdat‐Lasemi, F., Farhoudi, L., Hosseinikhah, S. M., Santos, R. D., & Sahebkar, A. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119235 · Cited by 14
Marmontel, O., Filippo, M. D., Marçais, C., Nony, S., Dumoux, M., Dancer, M. S., Caussy, C., Charrière, S., & Moulin, P. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.07.030 · Cited by 15
Lin, C.-Y., Chen, P., Hsu, H., Gao, W.-Y., Wu, M., & Yen, J.-H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012485 · Cited by 14
Lipoprotein profiles of fat distribution and its association with insulin sensitivity
Wei, D., Marrachelli, V. G., Melgarejo, J. D., Liao, C., Janssens, S. P., Verhamme, P. B., Vanassche, T., Aelst, L. N. L. V., Monleón, D., Redón, J., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.978745 · Cited by 17
Baker, B. F., Xia, S., Partridge, W., Kwoh, T. J., Tsimikas, S., Bhanot, S., & Geary, R. S. (2022) · Nucleic Acid Therapeutics · doi:10.1089/nat.2022.0044 · Cited by 15
Self-citationInhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia
Larouche, M., Khoury, É., Brisson, D., & Gaudet, D. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01179-y · Cited by 15
Andersson, P. U., & den Besten, C. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788015714-00474 · Cited by 22
Florentin, M., Kostapanos, M. S., Anagnostis, P. G., & Liamis, G. L. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1691523 · Cited by 15
Novel Therapeutics for Familial Chylomicronemia Syndrome
Izar, M. C. D. O., & Fonseca, F. A. H. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01295-x · Cited by 13
In vivo genome editing of ANGPTL3: a therapy for atherosclerosis?
Rhee, J., & Wu, J. C. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2018.38 · Cited by 13
Afanasieva, O. I., Владиславович, Е. М., & Pokrovsky, S. N. (2018) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2018-8-99-109 · Cited by 16
Smith, M. R., Glicksberg, B. S., Li, L., Chen, R., Morishita, H., & Dudley, J. T. (2017) · Pacific Symposium on Biocomputing (PSB) · doi:10.1142/9789813235533_0007 · Cited by 18
Treating Dyslipidemia in Type 2 Diabetes
Nelson, A. J., & Nicholls, S. J. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.005 · Cited by 14
RNA-based therapeutics in cardiovascular disease
Pham, T. P., Kremer, V., & Boon, R. A. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000724 · Cited by 13
Novel therapeutic targets and agents for pediatric dyslipidemia
Sunil, B., Foster, C., Wilson, D. P., & Ashraf, A. P. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211058323 · Cited by 14
Jiang, S., Ren, Z., Yang, Y., Liu, Q., Zhou, S., & Xiao, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115874 · Cited by 15
Recent Advances in the Management of Dyslipidemia: A Systematic Review
Feng, H. J. X., Yousaf, A., Moon, J., Ramiz, A., Krishma, U., & Pemminati, S. (2025) · Cureus · doi:10.7759/cureus.81034 · Cited by 22
Vo, Q. D. (2025) · PLoS ONE · doi:10.1371/journal.pone.0325330 · Cited by 14
The Role of VEGF Family in Lipid Metabolism
Zhou, Y., Zhu, X., Wang, H., Duan, C., Cui, H., Shi, J., Shi, S., Yuan, G., & Hu, Y. (2022) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201023666220506105026 · Cited by 12
Fukuhara, K., Furihata, K., Matsuoka, N., Itamura, R., Ramos, V. F. M. L., Hagi, T., Kalluru, H., Bramson, C., Terra, S. G., & Liu, J. (2023) · Clinical and Translational Science · doi:10.1111/cts.13498 · Cited by 12
The Future of Lipid-Lowering Therapy
Zwol, W. H.-V., Rimbert, A., & Kuivenhoven, J. A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071085 · Cited by 14
Iitake, C., Masuda, D., Koseki, M., & Yamashita, S. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01172-8 · Cited by 14
Personalized Medicine in Lipid-Modifying Therapy
Tomlinson, B., Lin, C.-H., Chan, P., & Lam, C. W. K. (2021) · Personalized Medicine · doi:10.2217/pme-2020-0110 · Cited by 12
Zhao, Y., Goto, M., Vaziri, N. D., Khazaeli, M., Liu, H., Farahanchi, N., Khanifar, E., Farzaneh, T., Haslett, P. A. J., Moradi, H., et al. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000257 · Cited by 14
Non-alcoholic fatty liver disease and liver secretome
Khan, M. S., Lee, C.-H., & Kim, S. G. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01419-w · Cited by 14
Hermel, M., Lieberman, M., Slipczuk, L. N., Rana, J. S., & Virani, S. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020459 · Cited by 12
Kraaijenhof, J. M., Tromp, T. R., Nurmohamed, N. S., Reeskamp, L. F., Langenkamp, M., Levels, J. H. M., Boekholdt, S. M., Wareham, N. J., Hoekstra, M., Stroes, E. S. G., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030476 · Cited by 14
Reducing residual cardiovascular risk with novel therapies
Davidson, M. H. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000672 · Cited by 12
Jin, L., Hong, N., Ai, X., Wang, J., Li, Z., Han, Z., Zhang, Q., Yu, Y., & Sun, K. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200320161835 · Cited by 12
Ganda, O. P. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000694 · Cited by 12
ANGPLT3 in cardio-metabolic disorders
Su, X. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06248-6 · Cited by 11
Martin, G. M., Hisama, F. M., & Oshima, J. (2020) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaa273 · Cited by 13
ANGPTL3 as a target for treating lipid disorders in type 2 diabetes patients
Chen, J., Luo, Q., Yi, Y., Wang, J., Chen, P., Luo, F., & Fang, Z. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02352-1 · Cited by 12
Macrophage-endothelial cell crosstalk drives atherosclerotic plaque formation and progression
Zhang, C., Zhang, Y., Yu, Y., Zhou, M., Zhang, J., Fu, K., & Li, Y. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177879 · Cited by 11
Research advances in current drugs targeting hyperlipidemia (Review)
Zhao, H., Wang, Y., Li, Y., Cheng, R., & Chen, W. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13623 · Cited by 15
Evinacumab for the treatment of homozygous familial hypercholesterolemia
Gao, Y.-L., Zhang, B., & Yang, J. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2047934 · Cited by 10
RNA interference-based therapies for the control of atherosclerosis risk factors
Kettunen, S., Ruotsalainen, A., & Ylä‐Herttuala, S. (2022) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000972 · Cited by 12
Li, Z.-F., & Wu, N. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.911429 · Cited by 11
A New Modality in Dyslipidemia Treatment: Antisense Oligonucleotide Therapy
Kim, K., & Choi, S. H. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.3.250 · Cited by 11
Gene transfer and genome editing for familial hypercholesterolemia
Canepari, C., & Cantore, A. (2023) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2023.1140997 · Cited by 14
Morinaga, J., Kashiwabara, K., Torigoe, D., Okadome, Y., Aizawa, K., Uemura, K., Kurashima, A., Matsunaga, E., Fukami, H., Horiguchi, H., et al. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318880 · Cited by 10
Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease
Oikonomou, E. K., Xenou, M., Zakynthinos, G. Ε., Tsaplaris, P., Lampsas, S., Bletsa, E., Gialamas, I., Kalogeras, K. I., Goliopoulou, A., Gounaridi, M. I., et al. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230703161058 · Cited by 12
Biotechnology Approaches for the Treatment of Dyslipidemia
Parolini, C. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07017-6 · Cited by 10
Ibi, D., Blauw, L. L., Noordam, R., Dollé, M. E. T., Jukema, J. W., Rosendaal, F. R., Christodoulides, C., Neville, M. J., Koivula, R. W., Rensen, P. C. N., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.04.015 · Cited by 10
Bellosta, S., Rossi, C., Alieva, A. S., Catapano, A. L., Corsini, A., & Baragetti, A. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07293-w · Cited by 10
A bibliometric analysis of autophagy in atherosclerosis from 2012 to 2021
Zhang, F., Wang, R., Liu, B., & Zhang, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.977870 · Cited by 13
McPherson, R. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.311392 · Cited by 12
ANGPTL3 orchestrates hepatic fructose sensing and metabolism
Zhao, M., Linde-Garelli, K. Y., Zhang, Z., Toomer, D. J., Reghupaty, S. C., Jimenez, J. I., Voilquin, L., Wat, L. W., Fernández, D., & Svensson, K. J. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115962 · Cited by 9
Tomlinson, B., Chan, P., Zhang, Y., & Lam, C. W. K. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1801638 · Cited by 11
Lipid management to mitigate poorer postkidney transplant outcomes
Skulratanasak, P., & Larpparisuth, N. (2022) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000841 · Cited by 10
Phenome-wide Mendelian randomization study of plasma triglyceride levels and 2600 disease traits
Park, J. K., Bafna, S., Forrest, I. S., Duffy, Á., Márquez‐Luna, C., Petrazzini, B. O., Vy, H. M. T., Jordan, D. M., Verbanck, M., Narula, J., et al. (2023) · eLife · doi:10.7554/elife.80560 · Cited by 10
Recent advances and emerging therapies in management of dyslipidemias
Pulipati, V. P., & Davidson, M. H. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2020.08.007 · Cited by 9
Zhao, X., Li, J., Tang, X., Liu, R., Xu, J., Xu, L., Jiang, L., Huang, K., Tian, J., Feng, X., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.229 · Cited by 9
Gutiérrez-Castro, K. P., González, A. P., Caccavello, R. J., Garay‐Sevilla, M. E., & Gugliucci, A. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.12.016 · Cited by 9
Poststatin era in atherosclerosis management: lessons from epidemiologic and genetic studies
Yvan‐Charvet, L., & Cariou, B. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000505 · Cited by 10
Li, L., Burke, J., Venkatesh, S., & Sadana, P. (2019) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13138 · Cited by 11
Bypassing the LDL Receptor in Familial Hypercholesterolemia
Kersten, S. (2020) · New England Journal of Medicine · doi:10.1056/nejme2023520 · Cited by 9
Bepirovirsen/GSK3389404: Antisense or TLR9 agonists?
Vaillant, A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.09.002 · Cited by 9
Ference, B. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1163 · Cited by 8
A New Insight on Atherosclerosis Mechanism and Lipid-Lowering Drugs
Li, P., & Jiang, W. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm25321 · Cited by 8
Hyperlipidemia drives tumor growth in a mouse model of obesity-accelerated breast cancer growth
Vieira, R. F. L., Sanchez, S. R., Arumugam, M., Mower, P. D., Curtin, M. C., Jackson, A. E., Gallop, M. R., Wright, J., Bowles, A., Ducker, G. S., et al. (2025) · Cancer & Metabolism · doi:10.1186/s40170-025-00407-0 · Cited by 9
Lv, Q., Jiao, X., Yu, H., Sun, Q., Fan, L., Wang, Y., Sun, H., Du, Z., Li, L., Hu, C., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025955 · Cited by 9
Wu, M., Wu, Y., Tang, S., Huang, J., & Wu, Y. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1176267 · Cited by 9
Baker, B. F., Xia, S., Partridge, W., Engelhardt, J. A., Tsimikas, S., Crooke, S. T., Bhanot, S., & Geary, R. S. (2024) · Nucleic Acid Therapeutics · doi:10.1089/nat.2023.0026 · Cited by 9
Self-citationRossi, I., Marodin, G., Lupo, M. G., Adorni, M. P., Papotti, B., Dall’Acqua, S., & Ferri, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073708 · Cited by 10
Navigating Lipodystrophy: Insights from Laminopathies and Beyond
Krüger, P., Hartinger, R., & Djabali, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158020 · Cited by 11
Leander, K., Chen, Y., Vikström, M., Silveira, A. M. V., Fisher, R. M., Konrad, R. J., & Hooft, F. M. V. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.321308 · Cited by 9
Janssen, L. G. M., Jauhiainen, M., Olkkonen, V. M., Haridas, P. A. N., Nahon, K. J., Rensen, P. C. N., & Boon, M. R. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081214 · Cited by 9
Gomes, D. J., Wang, S., Goodspeed, L., Turk, K. E., Wietecha, T., Liu, Y.-J., Bornfeldt, K., O’Brien, K. D., Chait, A., & den Hartigh, L. J. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100174 · Cited by 11
Approach to patients with hypertriglyceridemia
Chait, A., & Feingold, K. R. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101659 · Cited by 11
Non-coding RNA-Associated Therapeutic Strategies in Atherosclerosis
Tang, Y., Li, H., & Chen, C. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.889743 · Cited by 8
A genotype-phenotype transformer to assess and explain polygenic riskPreprint
Lee, I., Wallace, Z. S., Wang, Y., Park, S., Nam, H., Majithia, A. R., & Ideker, T. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.23.619940 · Cited by 12
Metadata
- Authors
- Graham, M. J., Lee, R. G., Brandt, T. A., Tai, L.-J., Fu, W., Peralta, R., Yu, R., Hurh, E., Paz, E., McEvoy, B. W., Baker, B. F., Pham, N. C., Digenio, A., Hughes, S. G., Geary, R. S., Witztum, J. L., Crooke, R. M., & Tsimikas, S.
- Affiliations
- Ionis Pharmaceuticals (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-07-20
- Volume
- 377
- Issue
- 3
- Pages
- 222-232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2618984243
- Cited by
- 573
- References
- 23
- Citations by year
- 2026: 20 · 2025: 36 · 2024: 48 · 2023: 51 · 2022: 85 · 2021: 86 · 2020: 90 · 2019: 59 · 2018: 72 · 2017: 26
- FWCI
- 52.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- ANGPTL3, antisense oligonucleotides, triglyceride lowering, hypertriglyceridemia, LDL cholesterol, hepatic triglyceride content, atherosclerosis, insulin sensitivity, lipoproteins, apolipoprotein B, apolipoprotein C-III, loss-of-function mutations, pharmacokinetics
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Adult, Aged, Animals, Coronary Artery Disease, Disease Models, Animal, Double-Blind Method, Female, Humans, Lipids, Male, Mice, Inbred Strains, Middle Aged, Oligonucleotides, RNA, Messenger, Oligonucleotides, Antisense, Angiopoietins, Dyslipidemias, Atherosclerosis, Lipid Metabolism, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.